Immunic, Inc. (NASDAQ:IMUX) Receives Average Rating of “Buy” from Brokerages

Immunic, Inc. (NASDAQ:IMUX) has earned a consensus rating of “Buy” from the four analysts that are covering the firm, MarketBeat Ratings reports. Four investment analysts have rated the stock with a buy rating. The average twelve-month price objective among analysts that have covered the stock in the last year is $12.75.

A number of research firms have weighed in on IMUX. StockNews.com upgraded shares of Immunic from a “sell” rating to a “hold” rating in a research report on Tuesday, August 13th. B. Riley began coverage on Immunic in a research note on Tuesday, August 27th. They issued a “buy” rating and a $6.00 price target for the company. Leerink Partners restated an “outperform” rating and issued a $5.00 price objective on shares of Immunic in a research report on Monday. Finally, Piper Sandler reiterated an “overweight” rating and set a $28.00 target price on shares of Immunic in a research report on Tuesday, July 16th.

Immunic Trading Up 3.0 %

Shares of NASDAQ IMUX opened at $1.38 on Monday. Immunic has a 12-month low of $0.95 and a 12-month high of $1.92. The firm has a market capitalization of $124.31 million, a price-to-earnings ratio of -0.75 and a beta of 1.82. The firm has a 50 day moving average of $1.36 and a 200 day moving average of $1.31.

Immunic (NASDAQ:IMUX) last posted its quarterly earnings data on Thursday, August 8th. The company reported ($0.21) EPS for the quarter, topping the consensus estimate of ($0.23) by $0.02. During the same period in the previous year, the business earned ($0.54) earnings per share. Sell-side analysts predict that Immunic will post -0.94 EPS for the current year.

Institutional Trading of Immunic

Several hedge funds have recently modified their holdings of the company. Gratus Capital LLC increased its position in Immunic by 15.1% in the fourth quarter. Gratus Capital LLC now owns 1,941,454 shares of the company’s stock worth $2,912,000 after purchasing an additional 254,999 shares during the last quarter. Sierra Summit Advisors LLC purchased a new position in shares of Immunic in the 4th quarter worth $487,000. Vanguard Group Inc. increased its holdings in shares of Immunic by 100.7% in the 1st quarter. Vanguard Group Inc. now owns 3,394,047 shares of the company’s stock worth $4,480,000 after buying an additional 1,703,047 shares during the last quarter. BVF Inc. IL purchased a new stake in shares of Immunic during the 1st quarter valued at about $11,752,000. Finally, Janus Henderson Group PLC bought a new position in shares of Immunic in the 1st quarter valued at about $9,266,000. 51.82% of the stock is owned by hedge funds and other institutional investors.

About Immunic

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.